-
A HEALTH ECONOMIC AND ENVIRONMENTAL EVALUATION OF SUBCUTANEOUS PERTUZUMAB/TRASTUZUMABVERSUS INTRAVENOUS PERTUZUMAB/TRASTUZUMAB FOR HER2-POSITIVE BREAST CANCER IN DENMARK (HEREAFTER)
Mar 18, 2026, 21:38 PM -
ENHANCING CLINICAL TRIAL ELIGIBILITY CRITERIA DESIGN WITH GENERATIVE ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING
Mar 18, 2026, 21:38 PM -
OPERATIONALIZING PATIENT ENGAGEMENT IN RARE DISEASE VALUE RESEARCH LESSONS FROM DISEASE-SPECIFIC USE CASES
Mar 18, 2026, 21:38 PM -
EVALUATING THE QUALITY OF CLINICAL EVIDENCE FOR DIGITAL HEALTH SOLUTIONS ACROSS FIVE THERAPEUTIC AREAS: FINDINGS FROM PHTI ASSESSMENTS
Mar 18, 2026, 21:38 PM -
VALUE SETS FOR AQOL, EQ-5D, HUI, QWB AND SF-6D: A SYSTEMATIC REVIEW OF THEIR AVAILABILITY AND CHARACTERISTICS
Mar 18, 2026, 21:38 PM -
SOCIAL MEDIA CONVERSATIONS ON IMMUNE CHECKPOINT INHIBITORS: TREATMENT EXPERIENCES, SAFETY, ACCESS, AND PATIENT PERSPECTIVES
Mar 18, 2026, 21:38 PM -
COST-EFFECTIVENESS OF SINGLE-DOSE HPV VACCINATION IN NEPAL:AN ECONOMIC EVALUATION
Mar 18, 2026, 21:38 PM -
A COST-UTILITY ANALYSIS OF TOCILIZUMAB PLUS METHOTREXATE VERSUS METHOTREXATE ALONEIN RHEUMATOID ARTHRITIS IN INDIA, USING THE MARKOV STATE TRANSITION MODEL
Mar 18, 2026, 21:38 PM -
CYP2D6-GUIDED OPIOID PRESCRIBING AND CLINICAL OUTCOMES IN CHRONIC PAIN: EVIDENCE FROM THE ADOPT PGX TRIAL LINKED TO MEDICARE AND MEDICAID CLAIMS
Mar 18, 2026, 21:38 PM -
COST-EFFECTIVENESS OF SILVER-CONTAINING DRESSING IN PATIENTS WITH DIABETIC FOOT ULCERS IN KOREA
Mar 18, 2026, 21:38 PM -
DO DISPARITIES IN SURGICAL REFERRALS INDICATE PREJUDICE? EVIDENCE FROM A PHYSICIAN SITUATIONAL CHOICE EXPERIMENT
Mar 18, 2026, 21:38 PM -
IMPACT OF COMORBIDITIES ON SELF-REPORTED QUALITY-OF-LIFE IN US ADULTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE): A POOLED ANALYSIS OF THE 2016-2022 MEDICAL EXPENDITURE PANEL SURVEY (MEPS)
Mar 18, 2026, 21:38 PM -
FUTURE-PROOFING UK HTA: CAN NICE ABSORB MFN-INDUCED PRICE INCREASES?
Mar 18, 2026, 21:38 PM -
AN AUTOMATED NETWORK META-ANALYSIS FRAMEWORK INTEGRATING INTELLIGENT ALGORITHMS AND LARGE LANGUAGE MODELS
Mar 18, 2026, 21:38 PM -
DEVELOPMENT OF AN INDIVIDUAL-LEVEL SIMULATION MODEL TO ASSESS THE COST CONSEQUENCES OF CARDIOVASCULAR-RENAL-METABOLIC SCREENING POLICIES FROM A NATIONAL PAYER AND SOCIETAL PERSPECTIVE
Mar 18, 2026, 21:38 PM -
THE ROLE OF INNOVATIVE CONTRACTS IN ADDRESSING UNMET MEDICAL NEEDS FOR HIGH-BUDGET-IMPACT THERAPIES: EVIDENCE FROM THERAPEUTIC ANALOGUES AND IMPLICATIONS FOR OBESITY
Mar 18, 2026, 21:38 PM -
A NOVEL BIOMARKER FOR THE EARLY DETECTION OF DIABETIC KIDNEY DISEASE: A BUDGET IMPACT ANALYSIS
Mar 18, 2026, 21:38 PM -
A METHOD FOR CALCULATING THE TOTAL QALY OUTPUT AND THE MEAN COST/QALY ATTRIBUTABLE TO THE HEALTH SECTOR; THE CASE OF THE UK
Mar 18, 2026, 21:38 PM -
CAREGIVER BURDEN AND SOCIOECONOMIC IMPACT OF HE AND OHE AMONG INDIVIDUALS CARING FOR PATIENTS WITH CIRRHOSIS
Mar 18, 2026, 21:38 PM -
EVIDENCE FOR MEANINGFUL PATIENT BENEFIT OF PEGCETACOPLAN IN C3G AND PRIMARY IC-MPGN FROM THE VALIANT TRIAL
Mar 18, 2026, 21:38 PM
